Hexagon Bio is a Menlo Park, California-based biopharmaceutical company discovering next-generation antibody-drug conjugate (ADC) payload mechanisms by mining cytotoxic small molecules from microbial genomes. Its proprietary platform combines DNA sequencing, data science and synthetic biology to find natural-product payloads orthogonal to widely used topoisomerase and tubulin inhibitors. Lead program HEX-360, a HER2-targeting ADC with a novel translation-inhibitor payload, is moving toward first-in-human studies, with a pipeline aimed at solid tumors and hematological malignancies.
1
Round
1
Industry
5
Tags
Oct 23, 2026
Latest raise
Funding activity · 1 round
Oct 23, 2026
$62M
Series C+
Led by The Column Group
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
